Paclitaxel in Breast Cancer
Open Access
- 1 December 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 3 (6) , 373-389
- https://doi.org/10.1634/theoncologist.3-6-373
Abstract
Paclitaxel has emerged as an important agent in the treatment of breast cancer. The efficacy and tolerability of this agent, as well as its lack of cross‐resistance with anthracyclines, have spurred ...Keywords
This publication has 50 references indexed in Scilit:
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1996
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal Of Cancer, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- 345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)European Journal Of Cancer, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990